• 02/01/2023 - 11:15

  Ikonisys and Integrated Gulf Biosystems Group enter into Distribution Collaboration for Distribution of the Ikoniscope20 System in the Middle East Market

• 11/14/2022 - 18:28

  Ikonisys announces the launch of its instrument for high-volume customers, the Ikoniscope20max

• 10/27/2022 - 17:45

  Ikonisys publishes its 2022 half-year financial results and reviews its operational deployments

• 10/05/2022 - 23:19

  Ikonisys has signed a financing agreement of up to €5.1m of aggregate principal amount to continue its commercial and development strategy and has drawn down a first tranche

• 09/26/2022 - 18:00

  Ikonisys announces the installation of the Ikoniscope20 solution at a US leading urology laboratory

• 09/21/2022 - 14:19

  Ikonisys and Negma Group announce the end of their financing agreement

• 09/13/2022 - 18:47

  Ikonisys announces the start of a Distribution Collaboration with BioVendor Laboratory Medicine for Distribution of the Ikoniscope20 System in the Eastern European Market

• 07/26/2022 - 18:00

  Ikonisys reinforces its strategic collaboration with Empire Genomics following excellent results of optimized reagents in detection of bladder cancer cells

• 06/22/2022 - 18:00

  Ikonisys announces the first sale of the Ikoniscope20 solution including the newly added reagents to Comprehensive Urology

• 05/24/2022 - 18:00

  Ikonisys signs contract and initiates research activities with Politecnico di Milano, a world leading public scientific-technological university in the field of computer science and bioengineering

• 05/12/2022 - 18:30

  Ikonisys Partners With Evosciences Leasing To Support The Commercial Expansion In Europe And The Usa Of The Ikoniscope20

• 05/04/2022 - 23:00

  Ikonisys has signed a financing agreement of up to €6m of aggregate nominal amount to continue the commercial roll-out map

• 04/29/2022 - 20:00

  Ikonisys publishes its Full-Year Financial Results for 2021 and provides an update on its latest developments

• 03/29/2022 - 17:45

  Ikonisys announces its participation in the Investor Access forum

• 02/16/2022 - 18:30

  The Ikoniscope20 preliminary results obtained with University of Connecticut School of Medicine (Neag Cancer Center of UConn) in detecting rare cells surpass the standards of test in immuno-oncology

• 02/07/2022 - 18:45

  Ikonisys announces the successfull installation of the Ikoniscope20 at Tomalab, one of the largest genetic laboratories in Italy

• 02/01/2022 - 18:00

  Ikonisys SA announces the appointment of Gabriel Plan as France sales Director

• 01/26/2022 - 18:30

  Ikonisys announces the initation of coverage of its stock by Sphene Capital

• 10/29/2021 - 18:00

  Ikonisys publishes its half-year financial results for 2021 and provides an update on its developments since its IPO

• 09/30/2021 - 17:45

  Ikonisys sa welcomes us sales director, accelerating its growth and expansion plans in the usa

• 09/06/2021 - 17:45

  Initial results of a study, in collaboration with the uconn school of medicine, highlight the potential of ikonisys’ cell-based diagnostic platform in immuno-oncology

• 09/06/2021 - 17:45

  Initial results of a study, in collaboration with the uconn school of medicine, highlight the potential of ikonisys’ cell-based diagnostic platform in immuno-oncology

• 07/13/2021 - 19:30

  Succes of Ikonisys' initial public offering on Euronext Growth® Paris